Clinical Trial Update: Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial

View source ↗

Summary

A prospective observational Phase II trial is profiling immune responses in stage III non-small cell lung cancer patients treated with concurrent chemoradiation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Maastricht Radiation Oncology | Conditions: Carcinoma, Non-Small-Cell Lung | Status: ACTIVE_NOT_RECRUITING